Wisconsin Discovery Portal

Researcher: Hector DeLuca

[ printable ]
Areas of Expertise
  • Molecular function of vitamins and hormones
  • Metabolism and mechanism of action of vitamins A and D
  • How 1,25-dihydroxyvitamin D3 functions in target tissues
  • Forms of vitamin D and vitamin A active in correcting deficiency disease
  • Isolating genes to identify the proteins that are made in response to 1,25-dihydroxyvitamin D3
  • Molecular biology techniques, organic chemical techniques, physiological techniques, and cell biology techniques
  • Multiple sclerosis
  • Rheumatoid arthritis
  • Anti-transplant rejection drugs
Web Site Hector DeLuca's University Web Page
Curriculum Vitae (CV)
Issued Patent(s)
  • 8,993,547 - 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses, issued March 2015.
  • 8,987,235 - N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-vitamin D analogs and their uses, issued March 2015.
  • 8,940,916 - Crystallization of (20R)-2-methylene-19-nor-24-difluoro-1.alpha.,25-dihydroxyvitamin D3, issued January 2015.
  • 8,884,039 - Crystallization of (20R) and (20S) analogs of 2-methylene-19-nor-24-dimethyl-1.alpha.,25-dihydroxyvitamin D.sub.3, issued November 2014.
  • 8,785,422 - A-ring modified 19-nor-vitamin D analogs and their uses, issued July 2014.
USPTO Published Applications
  • 20140187522 - Use of 2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism, published July 2014.
  • 20140206655 - (22E)-2-methylene-22-dehydro-1alpha,24,25-trihydroxy-19-nor-vitamin D3 analogs, published July 2014.
  • 20140155360 - Calcium formate for use as a dietary supplement, published June 2014.
  • 20140100203 - Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration, published April 2014.
  • 20140018332 - Methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin d analog with or without a retinoid, published January 2014.
Recent Publication(s)
  • Vitamin D deficiency independent of hypocalcemia elevates blood pressure in rats. Sundersingh F, Plum LA, DeLuca HF. Biochem Biophys Res Commun. 2015 June 12;461(4):589-591. doi: 10.1016/j.bbrc.2015.04.069. Epub 2015 April 21.
  • Cholecalciferol or 25-hydroxycholecalciferol neither prevents nor treats adenomas in a rat model of familial colon cancer. Irving AA, Plum LA, Blaser WJ, Ford MR, Weng C, Clipson L, DeLuca HF, Dove WF. J Nutr. 2015 February;145(2):291-298. doi: 10.3945/jn.114.204396. Epub 2014 December 24.
  • UV light selectively inhibits spinal cord inflammation and demyelination in experimental autoimmune encephalomyelitis. Wang Y, Marling SJ, Beaver EF, Severson KS, Deluca HF. Arch Biochem Biophys. 2015 February 1;567:75-82. doi: 10.1016/j.abb.2014.12.017. Epub 2014 December 23.
  • The vitamin D receptor in the proximal renal tubule is a key regulator of serum 1α,25-dihydroxyvitamin D₃. Wang Y, Zhu J, DeLuca HF. Am J Physiol Endocrinol Metab. 2015 February 1;308(3):E201-205. doi: 10.1152/ajpendo.00422.2014. Epub 2014 November 25.

View Hector DeLuca's publications at PubMed.
Recent Artistic Works
  • Intra-University Collaboration: McArdle Laboratory for Cancer Research
  • Shaanxi University of Technology, Vitamin D Research Institute
Research Tools
Research Facilities
E-mail Address [email protected]
Phone Number 608-262-1620
Current University UW–Madison
Department Biochemistry
Title Professor
Other Appointments President and CEO, Deltanoid Pharmaceuticals
Address Line 1 271A DeLuca Biochemistry Laboratories
Address Line 2 433 Babcock Drive
City Madison
State WI
Zip Code 53706
Bachelor's Degree B.A., University of Colorado
Master's Degree
PhD Ph.D., UW–Madison, Biochemistry
Other Degrees Hon. D.Sc, University of Colorado
Hon. D.Sc, Medical College of Wisconsin
Hon. Dr.Med, Karolinska Institute
Technologies Available for Licensing Modified Retinoid Compounds with Reduced Toxicity

Vitamin D Compounds for the Treatment of Ocular Hypertension

Vitamin D Analog “N-23” for Cancer Prevention and Treatment

Vitamin D Analog for Cancer Prevention and Treatment

Vitamin D Analog “Me-Cvit” Potentially Useful to Inhibit Hypercalcemia, Treat Cancer

Vitamin D Analogs “DO-REVA” and “DO-REVB” for Cancer Prevention and Treatment

Crystallized Vitamin D Compound Known as “NEL”

Vitamin D Analog “AB-47” for Cancer Prevention and Treatment

Vitamin D Analogs for Treating Bone Cancers and Diseases

Vitamin D Analog “CPA-1” for Treating and Preventing Deadliest Cancers

Vitamin D Analog “TS-17” for the Treatment of Cancer, Particularly Leukemia and Lung Cancer

Vitamin D Analog “UW-05” for Skin Therapy, Parathyroid and Autoimmune Disease Treatment

Preparations and Uses of an Endogenous Aryl Hydrocarbon Receptor

Vitamin D Analog for the Treatment of Cancer, Psoriasis and Osteoporosis




A New Phosphate Binder for Blocking Phosphate Absorption and Reducing Hyperphosphatemia

Treating Multiple Sclerosis with UV Light

Crystallized Vitamin D Compound Known as “20DCM”

Crystallized Vitamin D Analog 2-Methylene-18,19-Dinor-1Alpha-Hydroxy-Homopregnacalciferol

Vitamin D Analogs “1D-QM” and “1D-QMS” for Cancer, Bone Disease Therapy

Vitamin D Analogs “2EG” and “T-2EG-S” for Treating Cancer and Bone Disease

Vitamin D Analogs “3D-QM” and “3D-QMS” for Treating Cancer and Bone Diseases

Crystallized Vitamin D Analog “SAG-2”

Crystallized Vitamin D Analogs “MET-1” and “MET-2”

Crystallized Vitamin D Analog “24F2-DM”

Crystallized Vitamin D Analog “F-24”

Vitamin D Analog “DA2HE” to Treat and Prevent Polyps, Hyperplastic Intestinal Disorders

Vitamin D Analogs “WT-51” and “WT-52” Boost Bone and Skin Health

Vitamin D Analogs 2MD and 2AMD Prevent Type 1 Diabetes without Inducing Hypercalcemia

Calcitonin and Calcitonin-Like Compounds for Multiple Sclerosis